

A Molecular Basis for the Exquisite CD1d-Restricted Antigen Specificity and Functional Responses of Natural Killer T Cells

Kwok S. Wun,^{1,7} Garth Cameron,^{2,7} Onisha Patel,¹ Siew Siew Pang,¹ Daniel G. Pellicci,² Lucy C. Sullivan,² Santosh Keshipeddy,³ Mary H. Young,⁴ Adam P. Uldrich,² Meena S. Thakur,³ Stewart K. Richardson,³ Amy R. Howell,³ Petr A. Illarionov,⁵ Andrew G. Brooks,² Gurdyal S. Besra,⁵ James McCluskey,² Laurent Gapin,⁴ Steven A. Porcelli,⁶ Dale I. Godfrey,^{2,8,*} and Jamie Rossjohn^{1,8,*}

¹The Protein Crystallography Unit, ARC Centre of Excellence in Structural and Functional Microbial Genomics, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia

²Department of Microbiology & Immunology, University of Melbourne, Parkville, Victoria 3010, Australia

³Department of Chemistry, University of Connecticut, Storrs, CT 06269-3060, USA

⁴Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, CO 80206, USA

⁵School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

⁶Department of Microbiology and Immunology, Albert Einstein College of Medicine, Room 416 Forchheimer Building, 1300 Morris Park Avenue, Bronx, NY 10461, USA

⁷These authors contributed equally to this work

⁸These authors contributed equally to this work

*Correspondence: godfrey@unimelb.edu.au (D.I.G.), jamie.rossjohn@monash.edu (J.R.)

DOI 10.1016/j.immuni.2011.02.001

SUMMARY

Natural killer T (NKT) cells respond to a variety of CD1d-restricted antigens (Ags), although the basis for Ag discrimination by the NKT cell receptor (TCR) is unclear. Here we have described NKT TCR fine specificity against several closely related Ags, termed altered glycolipid ligands (AGLs), which differentially stimulate NKT cells. The structures of five ternary complexes all revealed similar docking. Acyl chain modifications did not affect the interaction, but reduced NKT cell proliferation, indicating an affect on Ag processing or presentation. Conversely, truncation of the phytosphingosine chain caused an induced fit mode of TCR binding that affected TCR affinity. Modifications in the glycosyl head group had a direct impact on the TCR interaction and associated cellular response, with ligand potency reflecting the $t_{1/2}$ life of the interaction. Accordingly, we have provided a molecular basis for understanding how modifications in AGLs can result in striking alterations in the cellular response of NKT cells.

INTRODUCTION

Natural killer T (NKT) cells express specific $\alpha\beta$ T cell receptors (TCRs) that recognize glycolipid antigens (Ag) presented by the nonclassical MHC class I molecule CD1d (reviewed in Godfrey et al., 2004). Most human NKT cells express an invariant V α 24-J α 18 TCR α chain, paired with a V β 11 TCR β chain, whereas murine NKT cells similarly express an invariant V α 14-J α 18 TCR α chain, paired with one of three different TCR β chain V

genes (V β 8, V β 7, V β 2) of which V β 8.2, the homolog of V β 11, is the most common (reviewed in Bendelac et al., 2007; Godfrey et al., 2008). Upon activation, NKT cells rapidly produce an array of cytokines and can influence immune outcomes in a broad range of settings, including microbial immunity, tumor immunity, autoimmunity, and allergy (reviewed in Godfrey et al., 2004). α -galactosylceramide (α -GalCer) (Kawano et al., 1997), a synthetic α -glycolipid widely used for activating NKT cells, is considered as a surrogate for a largely unknown repertoire of natural NKT ligands and is now used experimentally in preclinical and clinical translational studies as a potent NKT cell agonist (reviewed in Brutkiewicz, 2006).

The structures of human and mouse NKT TCRs, unliganded and in complex with CD1d- α -GalCer, have been determined, as well as the mouse NKT TCR in complex with α -galactosyl-diacylglycerol (α -GalDAG) (Borg et al., 2007; Gadola et al., 2006; Kjer-Nielsen et al., 2006; Li et al., 2010; Pellicci et al., 2009). These ternary complexes showed a conserved docking strategy that differs from all known TCR-peptide-MHC interactions (reviewed in Godfrey et al., 2008). The invariant NKT TCR α chain dominates this interaction, with the CDR1 α loop interacting solely with the lipid Ag, whereas the CDR3 α loop plays a central role, contacting CD1d and the lipid Ag (Borg et al., 2007; Pellicci et al., 2009). The role of the human V β 11 and the homologous mouse V β 8.2 chain is essentially restricted to the CDR2 β loop that interacts with CD1d. Comparison of the mouse V β 8.2 and V β 7 NKT TCR-CD1d- α -GalCer complexes shows similar docking, although conformational changes alter some of the contacts between the TCR α chain with CD1d- α -GalCer, indicating that differential V β chain usage could impact on CD1d-restricted Ag specificity (Pellicci et al., 2009).

NKT TCRs can bind an array of different lipid-based Ags in complex with CD1d, including bacteria-derived lipid Ags such as α -glucuronosylceramides, α -galactosyl-diacylglycerols, and phosphatidyl-inositol mannosides, and mammalian lipid

molecules, including iGb3, GD3, and β -glucosylceramide (reviewed in Bratkiewicz, 2006; Godfrey et al., 2010). Structural studies have provided insight into how CD1d can present natural and synthetic Ags (reviewed in Godfrey et al., 2010), although it is mostly unknown at the structural level how alterations in the CD1d-Ag landscape affect NKT TCR recognition. Some insight into the adaptability of the NKT TCR to recognize distinct CD1d-restricted Ags arose from NKT TCR mutagenesis experiments that underscored the importance of the CDR1 α , CDR3 α , and CDR2 β loops, yet also showed that some NKT TCR residues that contact Ag were not essential (Borg et al., 2007; Florence et al., 2009; Mallevaey et al., 2009; Pellicci et al., 2009; Scott-Browne et al., 2007; Wun et al., 2008). Further, glycolipids with different lipid tail lengths can alter the affinity for the NKT TCR, with the mechanism speculated to occur through alterations of the F'-pocket of CD1d, a major point of contact with the NKT TCR (McCarthy et al., 2007; Sullivan et al., 2010). Whereas the NKT TCR α chain is invariant, the β chain plays a role in determining thresholds of Ag reactivity, and this effectively enables some NKT TCRs to differentiate between Ags (Mallevaey et al., 2009). Furthermore, the composition of the CDR3 β loop might determine CD1d autoreactivity to self-Ags (Matulis et al., 2010; Mallevaey et al., 2011, this issue). Nevertheless, how the NKT TCR can recognize distinct self- and nonself-CD1d-Ags and possesses the capacity to discriminate between closely related Ags remains unclear (Gapin, 2010).

Altered peptide ligands (APLs) can dramatically affect MHC-restricted T cell-mediated biological outcomes (Sloan-Lancaster and Allen, 2003), yet cause only slight conformational readjustments at the TCR-pMHC-I interface (Baker et al., 2000; Degano et al., 2000). Paralleling this, numerous synthetic agonist analogs of α -GalCer have been described that differ in the structure of the glycosyl head group and/or lipid tails (reviewed in Venkataswamy and Porcelli, 2010). These represent the glycolipid equivalent of APLs and have remarkably distinct effects on NKT cell function. Some analogs (such as OCH and C20:2) have the ability to promote T helper 2 (Th2) cell-biased responses (Yu et al., 2005), whereas others (such as α -C-glycoside) (Schmieg et al., 2003) promote T helper 1 (Th1) cell-biased responses. Thus, studies with glycolipid analogs demonstrate the feasibility of using these to manipulate the NKT cell response, which can translate to more tailored NKT cell-based therapies (reviewed in Cerundolo et al., 2009). However, to achieve more targeted NKT-based therapeutics requires a greater understanding of the molecular basis of antigenic modulation of the NKT cell response. Here we report the structural and functional correlates of NKT TCR recognition of a series of closely related CD1d-restricted altered glycolipid ligands (AGLs). Our findings provide a systematic analysis of the mechanisms by which NKT TCR interactions with closely related glycolipid ligands presented by CD1d influences fine specificity and functional responses.

RESULTS

Affinity Hierarchy for the Glycolipid Antigens

α -GalCer, also known as KRN7000, is the prototypical agonist for NKT cells that possesses an 18C phytosphingosine and a 26C acyl chain (Kawano et al., 1997). Because many analogs of this Ag have been generated that promote distinct NKT cell

responses (reviewed in Venkataswamy and Porcelli, 2010), a critical question is whether the altered functionality is determined by their differential impact on TCR binding. We have investigated a panel of 10 different AGLs (Figures 1A–1J): (1) α -GalCer, (2) OCH, with C9 phytosphingosine and C24:0 acyl chains (Miyamoto et al., 2001); (3) C20:2, a C20 acyl chain and *cis*-diunsaturation at C11 and 14 (Yu et al., 2005); (4) α -GlcCer, identical ceramide component to C20:2, but α -linked glucosyl head group (Jervis et al., 2010); (5) 3',4''-deoxy- α -GalCer, both the 3'-OH of the sugar and the 4'-OH of the sphingoid base are removed (Raju et al., 2009); and (6) 4',4''-deoxy- α -GalCer, both the 4'-OH of the sugar and the 4'-OH of the sphingoid base are removed (Raju et al., 2009). To control for the dual modifications separately, we synthesized a new AGL (7), 4'-deoxy- α -GalCer, with a 4'-deoxy-sugar but retaining the 4'-OH group on the sphingoid base. For functional studies (below) we also analyzed (8) the 4''-deoxy- α -GalCer AGL (with an α -Gal sugar, but lacking the 4'-OH on the sphingoid base). We also included (9) α -GalCer (C24) and (10) α -GlcCer (C24), both with 24C acyl and 18C sphingosine chains, further enabling a direct comparison of the effect of modifying the orientation of the 4'-OH position of the sugar.

First, we determined the affinity of the interaction between the mouse V β 8.2 NKT TCR and the CD1d-AGL complexes by using surface plasmon resonance (SPR). Purified mouse CD1d was loaded with the eight individual AGLs or α -GalCer as a positive control. The affinity as determined by responses at equilibrium (equilibrium dissociation constant, K_{Deq}) of the TCR for mCD1d- α -GalCer was \sim 0.059 μ M, similar to previous reports. In contrast, the NKT TCR affinity for some, but not all, of the CD1d-AGL complexes deviated from that of CD1d- α -GalCer (Figures 2A–2I; Table S1 available online). For example, the affinity of the NKT TCR-CD1d- α -GalCer (C20:2) interaction, at 0.068 μ M (Figure 2C), and the NKT TCR-CD1d- α -GalCer (C24) interaction (K_{Deq} = 0.049 μ M) (Figure 2H) was essentially identical to that of the positive control, indicating that the modifications to the extent of acyl chain saturation and truncation did not impact on NKT TCR affinity. This result is consistent with earlier studies based on α -GalCer-CD1d tetramer versus C20:2-CD1d tetramer dissociation from cells (Im et al., 2009). The CD1d-OCH complex exhibited \sim 0.3 μ M affinity for the NKT TCR (Figure 2B), approximately 20% of the affinity of the NKT TCR-CD1d- α -GalCer interaction. Although this is broadly consistent with previous avidity studies with CD1d tetramer dissociation, this affinity was still higher than expected from earlier studies (Im et al., 2009; Sullivan et al., 2010). This discrepancy may reflect differences between molecular affinity and tetramer avidity. Nonetheless, given that composition of the solvent-exposed sugar is identical between OCH and α -GalCer, these data suggested that the modified sphingosine chain, which was buried within the F'-pocket, can indirectly affect head group presentation or CD1d conformation and therefore NKT TCR recognition. The affinity of the NKT TCR-CD1d-3',4''-deoxy- α -GalCer interaction, at \sim 0.2 μ M (Figure 2E), was only approximately 30% of the affinity compared to the positive control, suggesting that the 3'-OH moiety of the galactosyl headgroup influenced, but was not critical for, the interaction. In contrast, the α -GlcCer (C24) and the α -GlcCer (C20:2) exhibited a much reduced affinity (K_{Deq} of 0.55 μ M and 0.68 μ M, respectively), suggesting that the 4'-OH moiety was a key determinant in the NKT TCR interaction (Figures 2D and




Figure 1. Schematic of α -GalCer and the AGLs

(A) α -GalCer, (B) OCH, (C) α -GalCer (C20:2), (D) α -GlcCer (C20:2), (E) 3',4''-deoxy- α -GalCer, (F) 4',4''-deoxy- α -GalCer, (G) 4'-deoxy- α -GalCer, (H) 4''-deoxy- α -GalCer, (I) α -GalCer (C24), and (J) α -GlcCer (C24).

2)]. Consistent with this, the two 4'-deoxy- α -GalCer AGLs (Figures 2F and 2G), which also differ from α -GalCer via modifications at the 4'-OH position on the sugar, also exhibited a much reduced affinity, at $\sim 0.5 \mu\text{M}$. Thus, the 4'-OH moiety on the galactose headgroup was a key determinant in the NKT TCR

interaction, and furthermore, modification of the 4''-OH group on the sphingosine chain did not impact on the lower-affinity NKT TCR interaction with these AGLs.

Given that the affinity of the NKT TCR-CD1d-Ag interaction may not necessarily correlate with ligand potency, we also determined the kinetic rate constants of these interactions (Figures 2A–2I). There was a very good correlation between the K_D calculated by kinetic and equilibrium analyses and the residual plots, and low χ^2 values indicated that the kinetic rate constants were measured accurately. In comparison to the association and dissociation rate constants typical of TCR-pMHC interactions (van der Merwe and Davis, 2003), the NKT TCR engages CD1d-AGL complexes with fast on rates (k_a) and slow off rates (k_d), with a long $t_{1/2}$ life of approximately 20 s for the NKT TCR-CD1d- α -GalCer-positive control interaction. AGLs with modifications in the acyl tail did not appreciably affect the k_a or k_d of the interaction, whereas OCH impacted negatively on the association constant, which is suggestive of an induced fit mechanism for TCR-CD1d-OCH ligation. Interestingly, the AGLs with modifications in the glycosyl headgroup had a greater effect on the off rate than the on rate, with the off rate increasing by up to a factor of 10, and as such the $t_{1/2}$ life of these interactions were markedly shorter. Thus, these AGLs did not impact on the formation of the NKT TCR-CD1d-AGL complex, but resulted in less stable complexes being formed.

In summary, the structural modifications represented by these CD1d-AGL complexes showed different effects on the affinity of the NKT TCR interaction, with the following hierarchical order: α -GalCer = α -GalCer (C20:2) = α -GalCer (C24) > 3',4''-deoxy > OCH > 4'-deoxy = 4',4''-deoxy = α -GlcCer (C20:2) = α -GlcCer (C24). When the $t_{1/2}$ life was used as a guide, this order was preserved, with the exception of OCH, which had a markedly longer half life when compared to that of the 3',4''-deoxy AGL.

NKT Cell-Proliferative Response Shows a Contrasting Hierarchy to Affinity Measurements

To investigate the relationship between the affinity of the AGLs and their ability to induce NKT cell proliferation, the AGLs were tested in an in vitro assay with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled, NKT cell-enriched thymocytes cocultured with splenocytes derived from *Tcra*^{J^m1Tg} mice (*J α 18^{-/-}*) as a source of Ag-presenting cells (APC) (Figures 3A and 3B). Structural variations within the ceramide component had the greatest impact on NKT cell proliferation, especially evident at the low dose of 1 ng/ml. At this concentration, the AGLs with nontruncated sphingosine and acyl chains all produced robust proliferative responses. OCH also induced proliferation at 1 ng/ml; however, this was consistently weaker in comparison to the nontruncated AGLs. The major difference between OCH and α -GalCer is the truncated C9 instead of C18 phytosphingosine chain, although OCH also has a slightly shorter C24 acyl chain. The reduced NKT cell proliferation with OCH appeared to be due to the phytosphingosine chain truncation because the C24 acyl chain variant of α -GalCer drove proliferation to a similar extent to C26 α -GalCer. In contrast, the AGLs containing two double bonds within the acyl chain (C20:2 and α -GlcCer C20:2) barely induced NKT cell proliferation at 1 ng/ml. They were, however, able to induce proliferation at a higher dose (100 ng/ml) to a similar degree as their fully saturated




Figure 2. Analysis of the Interaction between Vβ8.2 NKT TCR and the CD1d Analogs as Assessed by Surface Plasmon Resonance

SPR sensograms showing the interaction between Vβ8.2 NKT TCR and CD1d loaded with (A) α-GalCer, (B) OCH, (C) C20:2, (D) α-GlcCer, (E) 3',4''-deoxy-α-GalCer, (F) 4',4''-deoxy-α-GalCer, (G) 4'-deoxy-α-GalCer, (H) α-GalCer (C24), or (I) α-GlcCer (C24). NKT TCR were injected over streptavidin-immobilized CD1d-Ag and simultaneously over a control cell containing unloaded CD1d. Top: Sensograms show the binding (response units, RU) of increasing concentrations of TCR to CD1d-Ag after baseline subtraction, displaying data points overlaid with curve fits. Bottom: Saturation plots demonstrating equilibrium binding of NKT TCR to immobilized CD1d-Ag. The affinities derived by equilibrium analysis (K_{Deq}) were equivalent to those derived by kinetic analysis.

counterparts. This suggested that modifications in the degree of saturation within the acyl chain can have an impact on the efficacy of glycolipid ligands as NKT cell agonists. In further support of this, α-GlcCer with a C24 saturated acyl chain induced similar NKT cell proliferation to α-GalCer with the C24 acyl chain. Given that the hierarchy in terms of proliferative response is clearly different from the affinity data, this suggested that the potency of the AGLs for inducing proliferation of NKT cells did not correlate precisely with the affinity or kinetics of the NKT TCR interac-

tions. This implied that other factors besides the equilibrium binding affinity or kinetics of the NKT TCR can contribute to the biological responses of NKT cells. This is consistent with reports showing that APC processing and presentation can vary for different glycolipid ligands, with some, such as α-GalCer, being more dependent on CD1d internalization, lysosomal processing, and re-expression in the context of plasma membrane lipid rafts than others, such as OCH and C20:2 (Bai et al., 2009; Im et al., 2009; Sullivan et al., 2010). Therefore, we




Figure 3. NKT Cell-Proliferative Response to AGLs
 (A and B) CFSE-labeled thymocytes enriched for NKT cells were cultured for 3 days with glycolipid-pulsed *Tcr α -J^{tm1Tg}* (*J α 18^{-/-}*) splenocytes.

also established a plate-bound CD1d assay to test the ability of the different analogs in the absence of APCs. This approach was used to assess the activation of an NKT cell hybridoma (not shown), as well as proliferation of freshly isolated NKT cells (Figure 3C). In both cases, the hierarchy of the response was clearly distinct to that observed when APCs were used and correlated more closely with the affinity and $t_{1/2}$ life of the ligands as determined by our SPR experiments. Collectively, these studies support the concept that whereas TCR affinity for different AGLs can influence NKT cell proliferation, differential Ag presentation of these ligands appears to be a major factor in determining the threshold of the proliferative response.

Cytokine Response Correlates with Affinity Hierarchy

Whereas NKT cells are capable of producing a broad range of cytokines in response to α -GalCer (reviewed in Godfrey et al., 2004), the amounts and ratio of the different cytokines produced may be modulated in response to different glycolipid AGLs (Im et al., 2009). Therefore, we tested cells and cell supernatants from similar cultures to those shown in Figures 3A and 3B for cytokine production. IFN- γ production by NKT cells was assessed by intracellular cytokine staining (ICS) whereas the production of IFN- γ , IL-4, IL-13, and IL-17 within the culture supernatant was determined with a cytometric bead array (CBA) assay after 8 hr stimulation with each of the AGLs (Figures 4A and 4B). Cytokine assays were tested after stimulation with the higher dose (100 ng/ml) at which proliferative responses to the AGLs were all comparable (Figures 3A and 3B). Interestingly, cytokine production by NKT cells did not correlate with proliferative potential for the AGLs under similar culture conditions. For example, the AGLs with unmodified galactose residues (α -GalCer, 4''-deoxy- α -GalCer, C20:2, OCH, and α -GalCer (C24)) induced the highest percentages of IFN- γ -producing NKT cells, whereas α -GlcCer (C20:2) repeatedly induced the least IFN- γ production of all and α -GlcCer (C24) was only marginally better at inducing IFN- γ production. The AGLs with the modified galactose moieties (3',4''-deoxy-, 4',4''-deoxy- α -GalCer, and 4'-deoxy- α -GalCer) were also less potent inducers of IFN- γ production from NKT cells in comparison to α -GalCer, despite a comparable capacity to induce NKT cell proliferation (Figure 4A). A similar pattern of cytokine production was observed for IFN- γ , IL-4, IL-13, and IL-17 in the culture supernatants in response to the different AGLs as measured by CBA (Figure 4B). Although some AGLs, such as OCH and C20:2, are considered to be Th2 cell-biasing Ags, this was not apparent in our assays. However, the Th2 cell-biasing capacity of these agents is considered to be more a reflection of the differential ability of these ligands to promote downstream IFN- γ production by bystander cells such as NK cells (Sullivan et al., 2010) rather

(A) A selection of representative flow cytometry profiles showing percent proliferated cells based on decreased CFSE intensity of α -GalCer-CD1d tetramer⁺ NKT cells at each AGL dose.
 (B) Graph depicts percentage divided cells (mean \pm SEM) from two to six independent experiments carried out as above.
 (C) MACS-enriched CD1d- α -GalCer tetramer⁺ thymic NKT cells (2×10^4) were CFSE labeled and cultured in plates precoated with either 10 or 1 μ g/ml CD1d-glycolipid complex. After 72 hr, CFSE dilution was measured by flow cytometry. Graphs depict the percentage of divided NKT cells \pm SEM of $n = 3$ replicates per group from a single experiment.




Figure 4. NKT Cell Cytokine Response to AGLs

(A and B) Thymocytes enriched for NKT cells were cultured for 8 hr with *Tcra*-*J α 18^{tm1Tg}* (*J α 18^{-/-}*) splenocytes previously pulsed with glycolipid (100 ng/ml). (A) The percentage of IFN- γ ⁺ α -GalCer-CD1d tetramer⁺ NKT cells was detected by ICS. Data are representative of four similar experiments. GolgiStop (BD Biosciences) was added for the last 4 hr.

(B) Culture supernatants were collected at 8 hr and cytokine amounts were quantified via CBA (BD Biosciences). Data are taken from one of at least three representative experiments (n = 5 replicates), graphs depict mean and SEM.

(C) Supernatants from cells stimulated by plate-bound CD1d-glycolipid complex at 10 μ g/ml dose, as described in Figure 3C, were harvested at 72 hr and cytokines analyzed by CBA. Graphs depict the concentration of cytokines \pm SEM of n = 3 replicates per group from a single experiment.

than a direct effect on NKT cell cytokine production. Indeed, direct analysis of cytokine production by NKT cells by ICS at 2 and 6 hr after in vivo challenge with OCH fails to reveal a Th2 cell bias by the NKT cells directly, when compared to α -GalCer (Sullivan et al., 2010). When we compared serum cytokines 2 and 20 hr after in vivo treatment with α -GalCer, OCH, and C20:2, the ratio of IL-4 to IFN- γ was similar to previous reports, showing that α -GalCer provided a more sustained IFN- γ response at 20 hr compared to C20:2 and OCH (Figure S1).

These data demonstrated that, in contrast to the proliferation of fresh NKT cells in response to the different AGLs presented by APCs, cytokine production by NKT cells in this assay broadly reflected the TCR affinity of these ligands. A similar pattern of cytokine production was detected in culture supernatants that were harvested from a plate-bound CD1d-AGL stimulation assay (Figure 4C).

Structures of the NKT TCR-CD1d-AGL Complexes

To address the structural basis of the fine specificity of the NKT TCR, we determined the structure of five NKT TCR-CD1d complexes containing different AGLs, namely OCH, C20:2, α -GlcCer, 3',4''-deoxy- α -GalCer, and 4',4''-deoxy- α -GalCer (Figure 5; Figure S2, Table S2). These complexes all crystallized in the same space group with similar unit cell dimensions, and therefore any structural differences observed can be attributed to the impact of the specific AGL.

In all five complexes, the NKT TCR adopted the characteristic docking mode initially observed for the NKT TCR-CD1d- α -GalCer complex (Borg et al., 2007; Pellicci et al., 2009), indi-

cating a conserved footprint without any repositioning of the NKT TCR caused by the AGLs (Figures 5A–5F). For four of the complexes (OCH, C20:2, 3',4''-deoxy-, and 4',4''-deoxy- α -GalCer), the buried surface area (BSA) upon ligation was 740–790 Å^2 , which compares closely to the BSA value of 760 Å^2 at the NKT TCR-CD1d- α -GalCer interface (Figures 5A–5C, 5E, and 5F). Within the footprints of these four complexes, the α chain contributed approximately three times more BSA than did the β chain, in which the V α 14- and J α 18-encoded interactions were mediated by the CDR1 α and CDR3 α , respectively (approximately 18% versus 57% BSA, respectively). Further, for all five complexes, the V β 8.2 interactions were mediated solely via the CDR2 β loop interacting with the α 1 helix of CD1d (approximately 24% BSA). This conserved set of CDR2 β -mediated interactions included Tyr48 β and Tyr50 β interacting with Glu83 and Lys86 of CD1d, the latter of which formed vdW interactions with Glu56 β (Table S3). This is comparable to what was previously observed for the NKT TCR-CD1d- α -GalCer interaction.

For the NKT TCR-CD1d- α -GlcCer complex, the BSA was only \sim 600 Å^2 , with the CDR1 α -, CDR3 α -, and CDR2 β -mediated interactions contributing 19%, 47%, and 33% BSA, respectively (Figure 5D). The lower BSA was attributable to the increased mobility of the CDR3 α loop within this complex, in which Leu99 α was not resolved in the electron density, and thus was not included in the final refined model. In the NKT TCR-CD1d- α -GalCer complex, Leu99 α made specificity-governing contacts with Arg79 and Val149 of CD1d (Table S3). Thus, the increased mobility of Leu99 α in the α -GlcCer complex would contribute toward the lower affinity of this interaction.

To evaluate whether the five AGLs caused any structural perturbations within CD1d, their respective CD1d Ag-binding clefts were compared to the NKT TCR-CD1d- α -GalCer complex and nonliganded counterparts if available (Figure 5G and not shown). Minimal root-mean-square-deviations (rmsd) (range

0.26–0.33 Å) were observed, indicating that the AGLs do not noticeably alter the structure of the CD1d-Ag binding cleft when ligated to the NKT TCR. Despite truncation and unsaturation of the acyl tails of C20:2 and α -GlcCer, the first seven carbons of their acyl tails adopted a similar conformation to that observed in CD1d- α -GalCer. For CD1d- α -GalCer, the tip of the 26C acyl tail curled back on itself to form stabilizing intra-vdw interactions. Because only 7 of the 20 acyl tail carbons were observed for the C20:2 ternary complex, it suggests that this acyl chain lacks these stabilizing intra-van der Waal (vdw) interactions and hence is mobile within the A'-pocket. Nevertheless, the A'-pocket of CD1d, when bound to the C20:2 and α -GlcCer, maintained a near-identical conformation when compared to CD1d- α -GalCer. Previous studies involving α -GalCer analogs with modifications on the acyl tails reported the presence of a spacer lipid in the A'-pocket (Schiefner et al., 2009); however, this was not observed in the NKT TCR-CD1d-C20:2 and α -GlcCer complexes. We suggest that this is attributable to the lengthier acyl chain analogs used in our studies, which could be expected to sterically hinder the binding of a spacer lipid.

Whereas the 4''-deoxy modification on the sphingosine tail of the 3',4''-deoxy- and 4',4''-deoxy α -GalCer AGLs did not affect the conformation of CD1d-Ag binding cleft, the 3'-OH on the sphingosine tail shifted slightly (~ 0.7 Å) to accommodate for this modification (Figure 6). The acyl and sphingosine chains of the 3',4''-deoxy- and 4',4''-deoxy AGLs, when bound to CD1d, adopted a similar conformation to that observed in the CD1d- α -GalCer complex.

Within the NKT TCR-CD1d-OCH complex, a spacer lipid was observed to occupy “the void” in the F'-pocket, essentially mimicking the end of the sphingosine tail as observed in CD1d- α -GalCer. However, the spacer lipid extended beyond this limit such that it almost protruded out of the F'-pocket and adopted a different conformation to the spacer lipid observed in the binary mouse CD1d-OCH structure (Figure 5G; Sullivan et al., 2010). Interestingly, when the OCH complex was compared to α -GalCer complex, the truncated sphingosine tail of OCH did not cause a repositioning of the F'-roof of CD1d (not shown) (McCarthy et al., 2007; Sullivan et al., 2010). However, a comparison of the CD1d-Ag binding clefts of the binary CD1d-OCH complex (Sullivan et al., 2010) and the NKT TCR-CD1d-OCH complex showed notable displacements (>1 Å) for Leu84, Val85, Lys86, Met87, Met88, and Val149. Further, Leu84 and Leu150 in the binary CD1d-OCH structure adopted very different conformations when compared to that observed in the NKT TCR-CD1d-OCH complex (Figure 5G). Although we cannot discount that these conformational differences between CD1d-OCH and NKT TCR-CD1d-OCH complexes were attributable to the spacer lipid, our results nevertheless indicated that the NKT TCR can operate via an induced-fit mechanism, whereby the NKT TCR molds the F'-pocket of the CD1d-Ag binding cleft to enable optimal engagement.

The Basis of NKT TCR Fine Specificity

Three of the α -GalCer AGLs, for which structures were determined (α -GlcCer, 3',4''-deoxy-, and 4',4''-deoxy- α -GalCer), contained glycosyl modifications—the only moiety of the CD1d-

restricted Ag that is surface exposed and thus directly contacted by the NKT TCR. The C20:2 and OCH AGLs possessed modifications in the acyl and sphingosine tails, respectively, and the interaction between the α -galactosyl head group of these latter two AGLs and the NKT TCR was essentially identical to that observed in the NKT TCR CD1d- α -GalCer interaction (Figures 6A–6E). Namely, for the C20:2 and OCH AGLs, the galactose ring sat underneath the CDR1 α loop and abuts the CDR3 α loop, forming vdw contacts on one face of the sugar ring with Arg95 α , Gly96 α , and Pro28 α . Arg95 α also made vdw contacts with the 3'-OH of the sphingosine chain. Gly96 α H-bonds to the 2'-hydroxyl, while Asn30 α H-bonds to both the 3'- and 4'-OH groups of the galactose ring (Figures 6C and 6E). Further, within the NKT TCR-CD1d-OCH and C20:2 complexes, the CDR3 α loop interacted with mCD1d. Arg95 α and Arg103 α flanked Arg79 from CD1d, and these positive charges were dissipated by neighboring acidic groups of Asp94 α , Glu83, and Asp80 (Figure 6D). Collectively, these CDR3 α loop and CD1d residues provided a focused network of polar and salt-bridging interactions.


As a direct result of modifications in the glycosyl head groups of α -GlcCer, 3',4''-deoxy-, and 4',4''-deoxy- α -GalCer AGLs, the interactions with the NKT TCR were modified to varying degrees, although there was no notable juxtapositioning in the side chain conformations of the NKT TCR to compensate for these modifications (Table S3). In the NKT TCR-CD1d-3',4''-deoxy- α -GalCer AGL complex, the loss of the 3'-OH resulted in a loss of a H-bond to Asn30 α from the CDR1 α loop and the vdw contacts with Gly96 α of the CDR3 α loop; in addition, a H-bond to Asp153 of CD1d was lost that could potentially have an impact on the stability of the CD1d-3',4''-deoxy- α -GalCer complex (Figure 6F). Collectively, the loss of these interactions also caused a slight tilting of the galactosyl head group, such that a maximal displacement of 0.7 Å with respect to the NKT TCR-CD1d-C20:2 complex was observed at the 5'-C position.

In the NKT TCR-CD1d-4',4''-deoxy- α -GalCer AGL complex, there was a greater shift of the galactosyl head group, with the entire ring being displaced down toward CD1d by approximately 0.9 Å. As a consequence, the lack of the 4'-OH moiety resulted in a loss not only of an H-bond to Asn30 α , but also of vdw contacts between the 3'-OH and CDR3 α loop and a lengthening of the H-bond between this 3'-OH moiety and Asn30 α (Figure 6G). Similarly, in the NKT TCR-CD1d- α -GlcCer AGL complex, the glycosyl head group was also displaced by approximately 0.9 Å, but in this instance it repositioned along the roof of the A'-pocket, which also resulted in the 3'-OH moiety being too far away to interact with Gly96 α of CDR3 α , as well as Asp153 of CD1d (Figure 6H). Within this complex, the 4'-OH of the glycosyl ring pointed in a different direction to the 4'-OH of the galactosyl ring, resulting in a lost H-bond with Asn30 α of the TCR and formation of an H-bond to the main chain of Gly155 of CD1d.

Accordingly, the effects of modification of the 4'-OH were more marked than for the 3'-OH, thereby providing a basis for understanding the greater dependency of the 4'-OH in NKT TCR recognition.

The Contribution of TCR β Chain to AGL Recognition

We have previously identified differences in the NKT TCR-CD1d- α -GalCer contacts depending on the use of V β 8.2 or V β 7 β chain (Pellicci et al., 2009). We therefore wanted to explore NKT TCR



V β 8.2 versus V β 7 usage in response to the AGLs used in this study. The percentage of NKT cells expressing V β 7 or V β 8.1-8.2 were analyzed after 3 days of *in vitro* proliferation in the presence of the different AGLs (Figures 7A–7B). Although all AGLs tested were capable of activating both V β 7 and V β 8.1-8.2 NKT cells, those with an altered 4'-OH on the sugar (α -GlcCer, α -GlcCer (C24), 4',4''-deoxy- α -GalCer, and 4'-deoxy- α -GalCer) induced higher percentages of V β 7⁺ NKT cells than cultures stimulated with α -GalCer, α -GalCer (C24), C20:2, and OCH. We also determined the degree of V β usage with cell division by gating in individual cell division peaks (Figures 7B–7C and data not shown). The bias toward V β 7 usage was dependent on the altered glycosyl head group, as indicated by the fact that both 4',4''-deoxy- α -GalCer and 4'-deoxy- α -GalCer showed a V β 7 bias, whereas 4''-deoxy α -GalCer did not. Similarly, both α -GlcCer (C20:2) and α -GlcCer (C24) showed a V β 7 bias, whereas α -GalCer (C24) and α -GalCer (C20:2) did not. Thus, for AGLs with an altered 4'-OH sugar moiety, especially α -GlcCer, that V β 7⁺ NKT cells were progressively enriched with each division cycle. Conversely, other AGLs, especially OCH, resulted in a loss of V β 7⁺ NKT cells with each progressive division cycle, a result that is consistent with an earlier study suggesting that OCH is preferentially recognized by V β 8⁺ NKT TCRs (Stanic et al., 2003). These data support the concept that AGLs have a direct impact on NKT cell function not only at the level of individual cells, but also at the population level where different NKT cell clones may be engaged depending on their TCR β chain usage. With this in mind, we engineered an NKT cell hybridoma to express the same TCR β chain that was used in our SPR and crystallography studies above. This hybridoma was challenged with the AGLs presented by *in vitro* generated bone marrow dendritic cells and the response measured by IL-2 production after 24 hr (Figure 7D). These experiments showed a hierarchy of IL-2 production that broadly reflected the affinity of the different AGLs for this particular NKT TCR. Namely, C20:2 and α -GalCer provided a clear IL-2 response at lower doses, whereas α -GlcCer did not stimulate at the same lower doses and, even at higher doses, it induced less IL-2 than α -GalCer and C20:2, whereas 3',4''-deoxy- α -GalCer, 4',4''-deoxy- α -GalCer, 4'-deoxy- α -GalCer, and OCH showed responses that were in between α -GalCer and α -GlcCer. This response was also distinct from the proliferation hierarchy observed for freshly isolated NKT cells (Figures 3A and 3B) but was largely consistent with the proliferation of fresh NKT cells in response to glycolipids presented by plate-bound CD1d (Figure 3C) and with the hier-

archy observed for the cytokine profiles derived from fresh NKT cells (Figure 4).

DISCUSSION

NKT cells can recognize a variety of CD1d-restricted glycolipid Ags, yet can discriminate between closely related CD1d-restricted ligands (reviewed in Godfrey et al., 2010; Venkataswamy and Porcelli, 2010). α -GalCer is a clinical trial phase I therapeutic of which many derivatives have been synthesized with a view to modulate the NKT cell response (reviewed in Venkataswamy and Porcelli, 2010). There is great interest in the ability of AGLs to modulate the NKT cell response, although the molecular basis for such effects remains unclear. Various explanations for the differential effects of AGLs on NKT cell function include differing affinities, pharmacokinetics, and involvement of different APCs; distinct CD1d loading kinetics; and distinct intracellular processing and presentation on the cell surface (Im et al., 2009; Sullivan et al., 2010; Venkataswamy and Porcelli, 2010). Our study has formally demonstrated the structural and biophysical basis for NKT TCR fine specificity against a set of closely related glycosylceramide analogs, which we have termed altered glycolipid ligands (AGLs). We have also related these molecular and biochemical observations to the NKT cell proliferative response, cytokine production, and NKT TCR V β usage. We selected ten AGLs, thereby gaining a broad perspective on the range of effects such modifications could impact on the structural and functional aspects of the NKT response.

In MHC-restricted immunity, subtle alterations of the antigenic peptide can markedly modulate the immune response. However, despite the dramatically different biological outcomes such APLs can elicit, only slight conformational readjustments are observed at the TCR-pMHC interface (Baker et al., 2000; Degano et al., 2000). Our findings mirror the APL studies of the MHC-restricted immune response, in that none of the AGLs studied had a profound impact on the NKT TCR-CD1d-Ag interaction. In MHC-restricted immunity, neither the affinity nor the half-life of the interaction has been an absolute predictor of ligand potency (Sloan-Lancaster and Allen, 2003), leading to other factors such as dwell-time, TCR-pMHC confinement models, and aggregate $t_{1/2}$ (t_a) being proposed as more reliable indicators of ligand potency (Aleksic et al., 2010; Govern et al., 2010). To compound matters, recent studies have shown that solution-based affinity measurements may not be fully reflective

Figure 5. Structure of the NKT TCR in Complex with Different α -GalCer AGLs

(A–F) Ribbon representation of the NKT TCR-CD1d-Ag structures with the corresponding footprints shown underneath.

(A) NKT TCR in complex with CD1d- α -GalCer (Pellicci et al., 2009).

(B) NKT TCR-CD1d-OCH.

(C) NKT TCR-CD1d-C20:2.

(D) NKT TCR-CD1d- α -GlcCer.

(E) NKT TCR-CD1d-3',4''-deoxy- α -GalCer.

(F) NKT TCR-CD1d-4',4''-deoxy- α -GalCer.

Footprints are color-coded based on the CDR loop contributions. TCR α , cyan; TCR β , green; CDR1 α loop, purple; CDR3 α loop, yellow; CDR2 β loop, orange; CD1d heavy chain, gray; β_2 m, dark gray; α -GalCer, magenta; C20:2, pink; α -GlcCer, red; 3',4''-deoxy- α -GalCer, brown; 4',4''-deoxy- α -GalCer, blue; OCH, light blue; spacer lipid, light green.

(G) NKT TCR induced fit of CD1d-OCH within the F'-pocket. Comparison of the binary CD1d-OCH (Sullivan et al., 2010) (yellow; spacer lipid, cyan) with the ternary NKT TCR-CD1d-OCH complex (light blue; spacer lipid, light green). α -GalCer is shown in magenta.




Figure 6. Comparison of the Glycosyl Head Group NKT TCR Interactions

- (A) α -GalCer.
- (B) CDR3 α loop interactions with CD1d- α -GalCer.
- (C) C20:2.
- (D) CDR3 α loop interactions with CD1d- α -C20:2.
- (E) OCH.
- (F) 3',4''-deoxy- α -GalCer.
- (G) 4',4''-deoxy- α -GalCer.
- (H) α -GlcCer.

of what occurs in situ (Huppa et al., 2010). Moreover, the myriad of TCR-pMHC docking modes suggests that a unifying parameter defining ligand potency in MHC-restricted immunity may prove challenging. In contrast, CD1d is monomorphic, the NKT TCR is semi-invariant, and at present the mode of NKT TCR-CD1d-Ag docking appears to be highly conserved. Thus, a priori, affinity or $t_{1/2}$ values may represent a more reliable indicator with respect to NKT TCR ligand potency. A confounding issue relating to CD1d-restricted Ags, however, is that modifications in the lipid tails can impact on ligand potency indirectly, and this certainly seems to be the case for AGLs with acyl chain modifications. Our data indicated that the altered potency arising from acyl chain modifications can arise only from alterations in Ag processing and presentation, as shown by the fact that they impacted neither on the NKT TCR-CD1d-AGL interaction nor on the affinity or kinetics of the interaction. Interestingly, however, modifications within the sphingoid base, as exemplified by the OCH AGL, impacted on the affinity of the interaction, ostensibly by causing a slower on rate, indicative of an induced-fit interaction, consistent with our structural data and recent observations in NKT TCR recognition of a microbial ligand (Li et al., 2010). This parallels similar observations in TCR-pMHC recognition, whereby buried alterations (polymorphisms) within the Ag-binding cleft of MHC can change the dynamics of the pMHC complex, which in turn alter the affinity of the TCR interaction (Archbold et al., 2009; Tynan et al., 2007). Thus, although the NKT TCR is considered to be relatively rigid (Borg et al., 2007), it can nevertheless operate in an induced-fit manner by reshaping the CD1d-Ag landscape, which is speculated to occur for the recognition of bulkier CD1d-restricted ligands such as iGb3 (Florence et al., 2009).

Modifications of the glycosyl headgroup directly reduced the $t_{1/2}$ of the interaction, with the NKT TCR exhibiting greater sensitivity for the 4'-OH position of α -GalCer than for the 3'-OH position. The 3'-OH modification resulted solely in a loss of interactions at this position, whereas modifications at the 4'-OH, as observed for the α -GlcCer and 4'-deoxy AGLs, altered the bonding network at both the 4' and 3' positions, thereby providing a molecular basis for understanding the greater sensitivity of the NKT TCR for the 4'-OH position of α -GalCer. These headgroup modifications resulted in reduced NKT cell activation (cytokine production), compared to their response to α -GalCer. Different AGLs may also drive expansion of different NKT cell clones, depending on their TCR β chain usage, which represents another means by which these ligands may differentially influence NKT cell activation. For example, the preferential V β 8 usage by NKT cells proliferating in response to OCH further supports the notion that the NKT TCR-CD1d interaction is finely tuned to subtle alterations within the F'-pocket. Conversely, modifications to the 4'-OH position of the sugar (α -GlcCer and 4',4''-deoxy α -GalCer) appeared to favor the V β 7+ NKT cells, which were more highly represented within more proliferated cells. These data indicate that the

Colors are as follows: CDR1 α loop, purple; CDR3 α loop, yellow; CD1d α helices, gray; α -GalCer, magenta; C20:2, pink; OCH, light blue; spacer lipid, light green; 3',4''-deoxy- α -GalCer, brown; 4',4''-deoxy- α -GalCer, blue; α -GlcCer, red; site of modification to analogs, cyan. H-bonds shown as dashed black lines.




Figure 7. V β 7 Usage and the CD1d-AGLs

(A–C) CFSE- or eFluor 670-labeled thymocytes enriched for NKT cells were cultured for 3 days with glycolipid-pulsed *Tcra-J^{tm1Tg} (J α 18^{-/-})* splenocytes, and V β expression of α -GalCer-CD1d tetramer⁺ NKT cells was analyzed by flow cytometry at distinct division cycles.

(A) An example of the approach to determine the percentage of undivided or division 6 NKT cells that were V β 7⁺ after culture in the presence of glycolipid.

(B) Percentage of V β 7 or V β 8.1–8.2⁺ cells within each division peak for three representative glycolipids.

(C) Summary of results showing the percentage of V β 7⁺ NKT cells within the most proliferated cells (from the last major generation) from two to six independent experiments.

(D) Dose-response analysis of an NKT cell hybridoma, engineered to express the NKT TCR used in SPR and crystallography studies (see [Experimental Procedures](#)), stimulated overnight with BMDCs plus the various AGLs at concentrations from 125 nM to 125 pM. Each data point represents the mean of triplicate IL-2 readings \pm SD from a single experiment. BMDCs derived from *Cd1d^{-/-}* mice used in the same conditions did not stimulate the hybridoma (data not shown).

hierarchical NKT response with respect to V β usage may be dependent on the fine-specificity requirements of the NKT TCR-CD1d interaction.

Our findings provide a molecular basis for our understanding of how different AGLs can promote distinct responses by CD1d-dependent NKT cells. Our findings simultaneously provide a rational basis for the design of tailor-made NKT-based therapeutics and a better understanding of the fine specificity of the NKT TCR.

EXPERIMENTAL PROCEDURES

Glycolipid Ags

The glycolipid analogs used in this study were synthesized as previously described (Jervis et al., 2010; Miyamoto et al., 2001; Raju et al., 2009; Yu et al., 2005). See [Supplemental Information](#) for synthesis of 4'-deoxy- α -GalCer.

Mice

C57BL/6 (B6) and *Tcra-J^{tm1Tg} (J α 18^{-/-})* (obtained from M. Taniguchi, RIKEN, Yokohama, Japan, and backcrossed 10 times to B6 background) mice were maintained under SPF conditions in the animal facilities of the Department of Microbiology and Immunology, The University of Melbourne. All experiments involving mice were approved by the University of Melbourne animal ethics committee and performed in accordance with ethics guidelines regarding the proper handling of animals.

CFSE Labeling and Proliferation Assay

Splenocytes from *Tcra-J^{tm1Tg} (J α 18^{-/-})* mice were pulsed overnight with glycolipid in the presence of IL-2 at 100 U/ml. Cells were harvested and overlaid on FCS, then centrifuged and resuspended in fresh media to remove excess glycolipid. Thymocytes were enriched for NKT cells by complement

depletion of anti-HSA- and anti-CD8-labeled cells. Dead cells were removed with Histopaque (Sigma) gradient centrifugation. Thymocytes were labeled with either 2 μ M 5-,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes) or 5 μ M eFluor 670 (eBiosciences) and incubated for 10 min at 37°C. Splenocytes and thymocytes were then combined at a ratio of 2:1 and cultured in 96-well flat-bottom plates. For proliferative analysis, cells were harvested after 72 hr and stained with anti-TCR β (BD Biosciences) and α -GalCer (PBS-44)-loaded CD1d tetramer. For V β analysis, cells were harvested after 72 hr and stained with either anti-V β 7 or V β 8.1–8.2 (BD Biosciences) and α -GalCer-loaded CD1d tetramer. Generational divisions of proliferating NKT cells were determined with FlowJo software (Treestar).

Cytokine Measurements

With similar stimulation conditions to the proliferation assay, IFN- γ production was analyzed by ICS on cells incubated with Golgistop (BD Biosciences) for the last 4 hr of an 8 hr culture. Cells were surface stained, fixed, and permeabilized (Cytofix-Cytoperm Kit, BD Biosciences) prior to staining with either anti-IFN- γ -phycoerythrin or anti-IFN- γ -allophycocyanin. Culture supernatants were collected after 8 hr and analyzed with CBA flex set for mice (BD Biosciences).

Protein Expression, Purification of the NKT TCR and CD1d

Cloning, expression, and purification of the mouse NKT TCR (V α 14-J α 18; V β 8.2) used in this study has been previously described (Pellicci et al., 2009). Cloning, expression, purification, and loading of the mouse CD1d protein were performed as described previously (Matsuda et al., 2000; Pellicci et al., 2009).

Ternary Complex Purification, Crystallization, Structure Determination, and Refinement

Purified mouse NKT TCR and CD1d-glycolipids were mixed and the ternary complexes were isolated by gel filtration on a Superdex 200 10-300 column, concentrated to 8 mg/ml in 10 mM Tris (pH 8.0), and 150 mM NaCl. Large crystals grew in 22% polyethylene glycol 400, 0.1 M ammonium acetate, and 0.1 M

BisTris (pH 5.6). Data were collected at the Australian Synchrotron Facility in Melbourne and processed and refined with standard software packages (see Supplemental Information).

Surface Plasmon Resonance Measurements and Analysis

The interaction between soluble NKT TCR and the CD1d-glycolipid complexes was analyzed by SPR with a Bio-Rad ProteOn XPR36 instrument (Hercules, CA) essentially as described previously (Pellicci et al., 2009).

Cell Lines and Retroviral Packaging

TCR α and TCR β constructs were cloned into retroviral plasmids and expressed by retroviral transduction of the 5KC-78.3.20 TCR α - and TCR β -negative hybridoma, as previously described (Scott-Browne et al., 2007).

Hybridoma Stimulation

A total of 5×10^4 hybridomas were cultured for 20 hr with 5×10^4 BMDCs, in complete RPMI medium containing 10% FCS, with the indicated concentration of AGLs. BMDCs were generated from single-cell suspensions from femurs and tibia of C57BL/6 mice or CD1d^{-/-} mice and cultured for 6 days in RPMI medium containing 10% FCS and 0.25% B78hi-conditioned medium (B78hi is a cell line that produces GMCSF). Hybridoma responses were measured by IL-2 ELISA in accordance with standard protocols.

Plate-Bound CD1d Stimulation Assay

Soluble mouse CD1d was loaded overnight with glycolipids at a 1:3 molar ratio, and flat-bottom 96-well plates were then coated with 60 μ l of 10, 1, or 0.1 μ g/ml CD1d-glycolipid solution for 3 hr at 37°C and then washed twice. MACS-anti-PE-beads were used to enrich CD1d tetramer-PE-labeled thymic NKT cells (95% pure) that were CFSE labeled and 2×10^4 added to each well. After 48 hr, cells were placed into fresh (uncoated) plates to remove stimulus, and at 72 hr, cells were analyzed by flow cytometry and cytokines in culture supernatant were analyzed by CBA.

ACCESSION NUMBERS

The coordinates of the mouse NKT TCR-CD1d-OCH; 3',4''- α -GalCer; 4',4''- α -GalCer; C20:2; and α -GlcCer have been deposited in the Protein Data Bank under the accession IDs 3ARB, 3ARD, 3ARE, 3ARF, and 3ARG, respectively.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, two figures, and three tables and can be found with this article online at doi:10.1016/j.immuni.2011.02.001.

ACKNOWLEDGMENTS

We thank the staff at the Australian synchrotron for assistance with data collection. We also thank D. Taylor, S. Chakravarti, and K. Field for assistance. We are grateful to P. Savage for generously providing α -GalCer (PBS44) for CD1d tetramer loading. This work was supported by the Cancer Council of Victoria, the National Health and Medical Research Council of Australia (NHMRC), and the Australian Research Council. G.C. is supported by CRI predoctoral scholarship and L.C.S. by an NHMRC RD Wright Fellowship. S.A.P. was supported by NIH grant AI45889. A.R.H. was supported by NIH grant R01GM087136. L.G. is supported by NIH grants (AI076463 and AI078246) and M.H.Y. by NIH training grant T32 AI07405. D.I.G. is supported by an NHMRC Principal Research Fellowship; J.R. is supported by an ARC Federation Fellowship. S.A.P. has received payments as a consultant for Vaccinex, Inc. (Rochester, NY) for work related to the development of therapeutics based on CD1d-pretreated glycolipids.

Received: August 18, 2010

Revised: December 23, 2010

Accepted: January 31, 2011

Published online: March 3, 2011

REFERENCES

- Aleksic, M., Dushek, O., Zhang, H., Shenderov, E., Chen, J.-L., Cerundolo, V., Coombs, D., and van der Merwe, P.A. (2010). Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. *Immunity* 32, 163–174.
- Archbold, J.K., Macdonald, W.A., Gras, S., Ely, L.K., Miles, J.J., Bell, M.J., Brennan, R.M., Beddoe, T., Wilce, M.C., Clements, C.S., et al. (2009). Natural micropolymerism in human leukocyte antigens provides a basis for genetic control of antigen recognition. *J. Exp. Med.* 206, 209–219.
- Bai, L., Sagiv, Y., Liu, Y., Freigang, S., Yu, K.O., Teyton, L., Porcelli, S.A., Savage, P.B., and Bendelac, A. (2009). Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen α GalCer. *Proc. Natl. Acad. Sci. USA* 106, 10254–10259.
- Baker, B.M., Gagnon, S.J., Biddison, W.E., and Wiley, D.C. (2000). Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling. *Immunity* 13, 475–484.
- Bendelac, A., Savage, P.B., and Teyton, L. (2007). The biology of NKT cells. *Annu. Rev. Immunol.* 25, 297–336.
- Borg, N.A., Wun, K.S., Kjer-Nielsen, L., Wilce, M.C., Pellicci, D.G., Koh, R., Besra, G.S., Bharadwaj, M., Godfrey, D.I., McCluskey, J., and Rossjohn, J. (2007). CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. *Nature* 448, 44–49.
- Brutkiewicz, R.R. (2006). CD1d ligands: The good, the bad, and the ugly. *J. Immunol.* 177, 769–775.
- Cerundolo, V., Silk, J.D., Masri, S.H., and Salio, M. (2009). Harnessing invariant NKT cells in vaccination strategies. *Nat. Rev. Immunol.* 9, 28–38.
- Degano, M., Garcia, K.C., Apostolopoulos, V., Rudolph, M.G., Teyton, L., and Wilson, I.A. (2000). A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. *Immunity* 12, 251–261.
- Florence, W.C., Xia, C., Gordy, L.E., Chen, W., Zhang, Y., Scott-Browne, J., Kinjo, Y., Yu, K.O., Keshipeddy, S., Pellicci, D.G., et al. (2009). Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands. *EMBO J.* 28, 3579–3590.
- Gadola, S.D., Koch, M., Marles-Wright, J., Lissin, N.M., Shepherd, D., Matulis, G., Harlos, K., Villiger, P.M., Stuart, D.I., Jakobsen, B.K., et al. (2006). Structure and binding kinetics of three different human CD1d- α -galactosylceramide-specific T cell receptors. *J. Exp. Med.* 203, 699–710.
- Gapin, L. (2010). iNKT cell autoreactivity: What is 'self' and how is it recognized? *Nat. Rev. Immunol.* 10, 272–277.
- Godfrey, D.I., MacDonald, H.R., Kronenberg, M., Smyth, M.J., and Van Kaer, L. (2004). NKT cells: What's in a name? *Nat. Rev. Immunol.* 4, 231–237.
- Godfrey, D.I., Rossjohn, J., and McCluskey, J. (2008). The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. *Immunity* 28, 304–314.
- Godfrey, D.I., Pellicci, D.G., Patel, O., Kjer-Nielsen, L., McCluskey, J., and Rossjohn, J. (2010). Antigen recognition by CD1d-restricted NKT T cell receptors. *Semin. Immunol.* 22, 61–67.
- Govern, C.C., Paczosa, M.K., Chakraborty, A.K., and Huseby, E.S. (2010). Fast on-rates allow short dwell time ligands to activate T cells. *Proc. Natl. Acad. Sci. USA* 107, 8724–8729.
- Huppa, J.B., Axmann, M., Mörtelmaier, M.A., Lillemeier, B.F., Newell, E.W., Brameshuber, M., Klein, L.O., Schütz, G.J., and Davis, M.M. (2010). TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. *Nature* 463, 963–967.
- Im, J.S., Arora, P., Bricard, G., Molano, A., Venkataswamy, M.M., Baine, I., Jerud, E.S., Goldberg, M.F., Baena, A., Yu, K.O., et al. (2009). Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. *Immunity* 30, 888–898.
- Jervis, P.J., Veerapen, N., Bricard, G., Cox, L.R., Porcelli, S.A., and Besra, G.S. (2010). Synthesis and biological activity of α -glucosyl C24:0 and C20:2 ceramides. *Bioorg. Med. Chem. Lett.* 20, 3475–3478.

- Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., et al. (1997). CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. *Science* 278, 1626–1629.
- Kjer-Nielsen, L., Borg, N.A., Pellicci, D.G., Beddoe, T., Kostenko, L., Clements, C.S., Williamson, N.A., Smyth, M.J., Besra, G.S., Reid, H.H., et al. (2006). A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. *J. Exp. Med.* 203, 661–673.
- Li, Y., Girardi, E., Wang, J., Yu, E.D., Painter, G.F., Kronenberg, M., and Zajonc, D.M. (2010). The V α 14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. *J. Exp. Med.* 207, 2383–2393.
- Mallevaey, T., Scott-Browne, J.P., Matsuda, J.L., Young, M.H., Pellicci, D.G., Patel, O., Thakur, M., Kjer-Nielsen, L., Richardson, S.K., Cerundolo, V., et al. (2009). T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. *Immunity* 31, 60–71.
- Mallevaey, T., Clarke, A.J., Scott-Browne, J., Young, M.H., Roisman, L.C., Pellicci, D.G., Patel, O., Vivian, J.P., Matsuda, J.L., McCluskey, J., et al. (2011). A molecular basis for NKT cell recognition of CD1d-self-antigen. *Immunity* 34, this issue, 315–326.
- Matsuda, J.L., Naidenko, O.V., Gapin, L., Nakayama, T., Taniguchi, M., Wang, C.-R., Koezuka, Y., and Kronenberg, M. (2000). Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. *J. Exp. Med.* 192, 741–754.
- Matulis, G., Sanderson, J.P., Lissin, N.M., Asparuhova, M.B., Bommineni, G.R., Schümperli, D., Schmidt, R.R., Villiger, P.M., Jakobsen, B.K., and Gadola, S.D. (2010). Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop. *PLoS Biol.* 8, e1000402.
- McCarthy, C., Shepherd, D., Fleire, S., Stronge, V.S., Koch, M., Illarionov, P.A., Bossi, G., Salio, M., Denkberg, G., Reddington, F., et al. (2007). The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. *J. Exp. Med.* 204, 1131–1144.
- Miyamoto, K., Miyake, S., and Yamamura, T. (2001). A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. *Nature* 413, 531–534.
- Pellicci, D.G., Patel, O., Kjer-Nielsen, L., Pang, S.S., Sullivan, L.C., Kyparissoudis, K., Brooks, A.G., Reid, H.H., Gras, S., Lucet, I.S., et al. (2009). Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. *Immunity* 31, 47–59.
- Raju, R., Castillo, B.F., Richardson, S.K., Thakur, M., Severins, R., Kronenberg, M., and Howell, A.R. (2009). Synthesis and evaluation of 3'- and 4''-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000. *Bioorg. Med. Chem. Lett.* 19, 4122–4125.
- Schiefner, A., Fujio, M., Wu, D., Wong, C.-H., and Wilson, I.A. (2009). Structural evaluation of potent NKT cell agonists: Implications for design of novel stimulatory ligands. *J. Mol. Biol.* 394, 71–82.
- Schmiege, J., Yang, G., Franck, R.W., and Tsuji, M. (2003). Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. *J. Exp. Med.* 198, 1631–1641.
- Scott-Browne, J.P., Matsuda, J.L., Mallevaey, T., White, J., Borg, N.A., McCluskey, J., Rossjohn, J., Kappler, J., Marrack, P., and Gapin, L. (2007). Germline-encoded recognition of diverse glycolipids by natural killer T cells. *Nat. Immunol.* 8, 1105–1113.
- Sloan-Lancaster, J., and Allen, P.M. (2003). Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. *Annu. Rev. Immunol.* 14, 1–27.
- Stanic, A.K., Shashidharamurthy, R., Bezbradica, J.S., Matsuki, N., Yoshimura, Y., Miyake, S., Choi, E.Y., Schell, T.D., Van Kaer, L., Tevethia, S.S., et al. (2003). Another view of T cell antigen recognition: Cooperative engagement of glycolipid antigens by Va14Ja18 natural TCR. *J. Immunol.* 171, 4539–4551.
- Sullivan, B.A., Nagarajan, N.A., Wingender, G., Wang, J., Scott, I., Tsuji, M., Franck, R.W., Porcelli, S.A., Zajonc, D.M., and Kronenberg, M. (2010). Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. *J. Immunol.* 184, 141–153.
- Tynan, F.E., Reid, H.H., Kjer-Nielsen, L., Miles, J.J., Wilce, M.C., Kostenko, L., Borg, N.A., Williamson, N.A., Beddoe, T., Purcell, A.W., et al. (2007). A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. *Nat. Immunol.* 8, 268–276.
- van der Merwe, P.A., and Davis, S.J. (2003). Molecular interactions mediating T cell antigen recognition. *Annu. Rev. Immunol.* 21, 659–684.
- Venkataswamy, M.M., and Porcelli, S.A. (2010). Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. *Semin. Immunol.* 22, 68–78.
- Wun, K.S., Borg, N.A., Kjer-Nielsen, L., Beddoe, T., Koh, R., Richardson, S.K., Thakur, M., Howell, A.R., Scott-Browne, J.P., Gapin, L., et al. (2008). A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. *J. Exp. Med.* 205, 939–949.
- Yu, K.O., Im, J.S., Molano, A., Dutronc, Y., Illarionov, P.A., Forestier, C., Fujiwara, N., Arias, I., Miyake, S., Yamamura, T., et al. (2005). Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. *Proc. Natl. Acad. Sci. USA* 102, 3383–3388.